BSE Live
Mar 20, 16:01Prev. Close
366.20
Open Price
373.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 20, 15:53Prev. Close
366.10
Open Price
367.25
Bid Price (Qty.)
385.05 (385)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of SMS Pharmaceuticals (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 8.16 | 5.89 | -0.83 | 7.35 | 7.39 | |
| Diluted EPS (Rs.) | 8.16 | 5.89 | -0.83 | 7.35 | 7.39 | |
| Cash EPS (Rs.) | 11.48 | 9.54 | 4.25 | 11.82 | 9.83 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 72.15 | 63.36 | 54.40 | 55.56 | 48.50 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 72.15 | 63.36 | 54.40 | 55.56 | 48.50 | |
| Revenue from Operations/Share (Rs.) | 88.29 | 83.79 | 61.67 | 61.41 | 66.53 | |
| PBDIT/Share (Rs.) | 16.38 | 14.30 | 7.02 | 14.12 | 14.71 | |
| PBIT/Share (Rs.) | 12.51 | 10.58 | 3.22 | 10.32 | 12.08 | |
| PBT/Share (Rs.) | 10.42 | 7.81 | 0.63 | 8.09 | 10.76 | |
| Net Profit/Share (Rs.) | 7.60 | 5.81 | 0.46 | 8.02 | 7.20 | |
| NP After MI And SOA / Share (Rs.) | 7.80 | 5.89 | -0.83 | 7.35 | 7.39 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 18.55 | 17.07 | 11.37 | 22.99 | 22.11 | |
| PBIT Margin (%) | 14.16 | 12.62 | 5.22 | 16.80 | 18.16 | |
| PBT Margin (%) | 11.79 | 9.32 | 1.02 | 13.17 | 16.17 | |
| Net Profit Margin (%) | 8.61 | 6.93 | 0.74 | 13.05 | 10.82 | |
| NP After MI And SOA Margin (%) | 8.83 | 7.02 | -1.35 | 11.96 | 11.10 | |
| Return on Networth/Equity (%) | 10.80 | 9.29 | -1.53 | 13.23 | 15.23 | |
| Return on Capital Employed (%) | 13.38 | 12.75 | 4.36 | 13.17 | 16.54 | |
| Return on Assets (%) | 5.99 | 4.81 | -0.80 | 7.23 | 7.69 | |
| Total Debt/Equity (X) | 0.49 | 0.52 | 0.55 | 0.55 | 0.53 | |
| Asset Turnover Ratio (%) | 0.72 | 0.74 | 0.60 | 0.61 | 69.33 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.72 | 1.62 | 1.61 | 1.92 | 1.59 | |
| Quick Ratio (X) | 0.84 | 0.91 | 0.73 | 0.64 | 0.88 | |
| Inventory Turnover Ratio (X) | 3.02 | 1.86 | 1.26 | 1.99 | 4.09 | |
| Dividend Payout Ratio (NP) (%) | 4.89 | 5.09 | -35.97 | 4.08 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 3.27 | 3.12 | 10.13 | 2.69 | 0.00 | |
| Earnings Retention Ratio (%) | 95.11 | 94.91 | 135.97 | 95.92 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 96.73 | 96.88 | 89.87 | 97.31 | 0.00 | |
| Coverage Ratios | ||||||
| Interest Coverage Ratios (%) | 7.83 | 5.16 | 2.71 | 6.33 | 9.16 | |
| Interest Coverage Ratios (Post Tax) (%) | 7.83 | 5.16 | 2.71 | 6.33 | 9.16 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 2,151.85 | 1,748.52 | 734.33 | 1,007.49 | 1,231.25 | |
| EV/Net Operating Revenue (X) | 2.75 | 2.47 | 1.41 | 1.94 | 2.19 | |
| EV/EBITDA (X) | 14.82 | 14.44 | 12.36 | 8.43 | 9.88 | |
| MarketCap/Net Operating Revenue (X) | 2.41 | 2.13 | 0.94 | 1.53 | 1.87 | |
| Retention Ratios (%) | 95.10 | 94.90 | 135.97 | 95.91 | 0.00 | |
| Price/BV (X) | 2.95 | 2.81 | 1.06 | 1.69 | 2.57 | |
| Price/Net Operating Revenue | 2.41 | 2.13 | 0.94 | 1.53 | 1.87 | |
| Earnings Yield | 0.04 | 0.03 | -0.01 | 0.08 | 0.06 |
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
09.02.2026
05.01.2026
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
14.11.2025
SMS Pharma Consolidated September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
12.11.2025
SMS Pharma Standalone September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
23.03.2026
22.03.2026
Sell-on-rise market? SBI Securities sees Nifty under pressure, picks two stocks for the week ahead
20.03.2026
Eris Lifesciences, Natco Pharma to launch generic Ozempic at 90% cheaper price
20.03.2026
Semaglutide’s patent expires today. What does it mean for patients, pharma players and Novo Nordisk?
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth